NASDAQ
1.10USD
+0.04 (+3.77%)
We have scored 4 news catalysts on Acurx Pharmaceuticals, Inc. (ACXP) over the past 12 months. The biggest single-day move next to one of them came Mar 19, 2026, when ACXP closed +27.3%: “Can Acurx Pharmaceuticals (ACXP) Climb 226.3% to Reach the Level Wall Street Analysts Expect?”. Coverage across the window leans positive (average ticker sentiment +0.55). Most of the impact sits in short squeeze potential and price momentum.
Dots are scored news catalysts — size = impact, color = sentiment. Tap one to read it.
Market cap
6.1M
P/E
—
EPS
—
Beta
-2.08
52W range
0.9457-7.54
Day range
1.06–1.12
Open
1.06
Prev close
1.06
Volume
35.1K
Avg volume
116.6K
Dividend
0.00
IPO
2021-06-25
Daily OHLCV with SMA overlays and session pivots. Draw your levels and trendlines on it, or ask the AI analyst what the price is reacting to.
Suppliers, customers, partners and competitors, derived from what the news actually says about Acurx Pharmaceuticals, Inc. — not a sector bucket. Click an edge to see the articles that established the link.
Latest scored catalyst for ACXP: .
Free · No account
Get a free daily PDF briefing — the last 24 hours of news, with summaries and the market-impact score for each story, delivered an hour before the open.
We’ll watch
Pre-filled from this story — remove any you don’t want. Add more tickers & tags or fine-tune your watchlist anytime — every email has an edit link, no account needed.
Free forever · one email a day, max · unsubscribe in one click.How it works
Acurx Pharmaceuticals, Inc. functions as a clinical-stage biopharmaceutical firm focused on developing innovative antibiotic treatments for bacterial infections. The company's primary drug candidate is ibezapolstat, an antibiotic that utilizes a novel mechanism of action by targeting the polymerase IIIC enzyme. Ibezapolstat has successfully completed Phase II clinical trials for addressing Clostridium difficile infections. Additionally, Acurx is progressing with ACX-375C, an investigational therapeutic suitable for both oral and injectable administration. This compound is being developed to combat various gram-positive bacteria, including resistant strains such as methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus, and penicillin-resistant Streptococcus pneumoniae. Acurx Pharmaceuticals, Inc. was established in 2017 and is headquartered in Staten Island, New York.
